Goldman Sachs
ARMP icon

Goldman Sachs’s Armata Pharmaceuticals ARMP Stock Holding History

Goldman Sachs’s Portfolio ARMP Stock Details ARMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-60,953
Closed -$624K – 6559
2026
Q1 		$624K Buy
60,953
+15,790
+35% +$133K ﹤0.01% 5454
2025
Q4 		$284K Buy
+45,163
New +$248K ﹤0.01% 5892
2023
Q1 		– Sell
-13,907
Closed -$17.2K – 5904
2022
Q4 		$17.2K Buy
+13,907
New +$36.2K ﹤0.01% 5714
2017
Q1 		– Sell
-112
Closed -$7K – 6736
2016
Q4 		$7K Buy
112
+3
+3% +$373 ﹤0.01% 6789
2016
Q3 		$23K Buy
+109
New +$25.1K ﹤0.01% 6710
2016
Q2 		– Sell
-2,316
Closed -$1.28M – 7008
2016
Q1 		$1.28M Buy
+2,316
New +$1.19M ﹤0.01% 3871

Other funds holding ARMP

MAM
Madison Asset Management Madison, Wisconsin $8.39B AUM 16.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Goldman Sachs's ARMP Position: Q2 2026 in Review

Goldman Sachs sold out of Armata Pharmaceuticals (ARMP) in Q2 2026, closing a stake of 60,953 shares — an estimated $624K sold.

Goldman Sachs first reported a position in ARMP in Q1 2016 and held it in 6 quarters. The position peaked at $1.28M in Q1 2016. 53 funds tracked by Wall St. Rank hold ARMP as of Q2 2026.

  • Goldman Sachs reported no remaining Armata Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 60,953 Armata Pharmaceuticals shares in Q2 2026, an estimated $624K.
  • Goldman Sachs first reported a position in Armata Pharmaceuticals in Q1 2016 and held it in 6 quarters.
  • Goldman Sachs's Armata Pharmaceuticals position peaked at $1.28M in Q1 2016.
  • 53 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.